Kurtlic serves as a policy consultant for the BPI, a role that involves providing guidance on policy matters.
Mona Kurtalic Appointed as Advisor for Politics at the BPI
Mona Kurtalic has taken on a new role as Advisor for politics within the Federal Association of the Pharmaceutical Industry (BPI) in Germany. She began her new position on February 1, 2023.
Kurtalic, a health economist, will be overseeing the association's communication strategies and public affairs activities. She will work alongside Sebastian Schuetze and Larissa Schmidt in her new role.
The BPI, with over 300 pharmaceutical companies under its wing, is a significant player in the pharmaceutical industry. It plays a crucial role in shaping health policy and advocating for the industry's interests in Germany. The organisation's headquarters are based in Berlin.
Kurtalic's expertise in health economics is expected to be beneficial in her new role. Prior to joining the BPI, she worked as a scientific assistant for the FDP's parliamentary group on health policy. This experience is likely to contribute to her success in her new role at the BPI.
The appointment of Kurtalic was announced on January 25, 2023. Her transition to the BPI marks a move from the FDP's parliamentary group on health policy.
In her previous role, Kurtalic worked alongside colleagues such as Sebastian Schuetze and Larissa Schmidt. It is expected that this collaborative relationship will continue in her new role at the BPI.
The BPI represents a professional organisation that advocates for the pharmaceutical industry in Germany. Kurtalic's primary responsibilities in her new role include advocating for the industry's interests in political discussions.
With her extensive background in health policy and economics, Kurtalic is well-positioned to make a significant impact in her new role at the BPI.
Science plays a crucial role in shaping health policies, and Mona Kurtalic, with her expertise in health economics, will be advocating for the pharmaceutical industry's interests in politics and health-and-wellness discussions at the BPI. Beyond politics, she is expected to be an essential figure in general-news concerning the pharmaceutical industry in Germany.
